EN PL

FDA: Bioanalytical Method Validation

20.09.2013
This guidance provides assistance to sponsors of investigational new drug applications (INDs), new drug applications (NDAs), abbreviated new drug applications (ANDAs), biologic license applications (BLAs), and supplements in developing bioanalytical method validation information used in human clinical pharmacology, bioavailability (BA), and bioequivalence (BE) studies that require pharmacokinetic (PK) or biomarker concentration evaluation. This guidance also applies to bioanalytical methods used for nonclinical pharmacology/toxicology studies.